Radalara Receives IRB Approval for Novel Radiation-Safety study at Houston Methodist Hospital

Houston, TX – October 27, 2025 – Radalara, a pioneering healthcare technology company focused on reducing radiation exposure in interventional suites, announced the approval of an Institutional Review Board (IRB)-approved study at Houston Methodist Hospital. This milestone marks a significant step forward in validating Radalara’s innovative computer vision device, which uses predictive analytics to forecast potential scatter radiation and enhance safety for operating room (OR) personnel from the dangers of ionizing radiation.

Houston Methodist Hospital, ranked as the top hospital in Texas by U.S. News & World Report, is renowned for its cutting-edge research and commitment to patient and staff safety. The study will test Radalara’s proactive technology in real-world interventional procedures, warning medical teams about potential scatter radiation.

Radalara (Radiation As Low As Reasonably Achievable) addresses a critical gap in current radiation monitoring systems, which are often reactive and report exposures after the fact – sometimes months later. The Radalara device predictive software allows users to modify behaviors and minimize exposure prior to the radiating event.

Ezekiel Fink, MD, Inventor and Co-Founder of Radalara, notes: “As a fluoroscopy expert, I am concerned about the long-term health effects of cumulative low-dose radiation on the many healthcare professionals who work in proximity to imaging equipment. This IRB-approved study will generate critical data to help refine our technology and enhance safety.”

The company has a working prototype, multiple patents filed with a filed non-provisional patent granted, and a clear path to FDA approval.

About Radalara
Radalara is dedicated to advancing radiation safety through innovative, predictive technology. By enabling real-time exposure reduction, we protect healthcare professionals and improve outcomes in interventional suites.